TALA partnered with Uniphar, a global leader in healthcare services, to deliver a high-impact event in Boston aimed at simplifying European market access for U.S. based pharma and biotech companies. With over 57 years of expertise, Uniphar provides end-to-end solutions that remove barriers to product launch, particularly in Europe’s complex regulatory landscape.
The Boston event brought together 40 industry leaders and strategic partners to explore the theme: “Elevating Access and Turning the Heterogeneity of Europe into Commercial Success.” With Europe’s fragmented reimbursement environment often proving a hurdle for U.S. companies, the event sought to demonstrate how Uniphar’s commercialisation platform accelerates access to life-changing therapies worldwide.
To raise the profile of the event, a keynote speaker with over two decades of experience in rare diseases and medtech innovation was secured to host the event. Their insights anchored the discussion around market access challenges and showcased practical pathways for success, reinforcing Uniphar’s positioning as a trusted global partner.
Post-event, TALA developed a comprehensive report summarising insights from the presentations, including case studies and key takeaways. This has since been used by Uniphar’s Business Development team across conferences and industry meetings, extending the event’s impact and driving meaningful conversations beyond Boston.
Through this strategic collaboration, Uniphar successfully strengthened its U.S. presence and reaffirmed its commitment to helping biotech and pharma companies unlock commercial success in Europe.